Mankind Pharma Ltd.
Pharma · NSE
52-week range
₹1,910 – ₹2,715
From 52w high
-10.5%
RSI (14)
78.6
vs SMA 50 / 200
↑ 50 · ↑ 200
Mankind Pharma (NSE: MANKIND) is a pharma sector stock trading at ₹2,423.10, up 2.34% over 12 months and 15.98% over the past 3 months, with trailing PE of 56.0x compressing to a forward PE of 40.6x on analyst consensus estimates across 20 analysts (1–5 scale, mean rating 2.0, lower = more constructive). The stock sits above both its 50-DMA (₹2,157.96) and 200-DMA (₹2,299.10) with RSI at 76.97, and carries a debt-to-equity ratio of 53.89 on a rising debt trend.
- ✓Revenue has grown at a 10.4% 5-year CAGR; forward PE of 40.6x represents a meaningful compression from the trailing multiple of 56.0x, reflecting analyst consensus expectations of earnings growth.
- ✓The stock is above both its 50-DMA (₹2,157.96) and 200-DMA (₹2,299.10), and is 10.77% below its 52-week high with three identified support levels at ₹2,217, ₹2,146.20, and ₹2,033.
- ✓Mankind recently completed full redemption of ₹1,250 crore in non-convertible debentures, reducing that specific debt obligation from its balance sheet.
- ✓Analyst coverage spans 20 analysts with a mean rating of 2.0 on a 1–5 scale (lower = more constructive), indicating a broadly constructive sentiment among the covering analyst community.
- ✗Quality score of 36 ranks 4th of 6 pharma/healthcare sector peers, below MAXHEALTH (54), SUNPHARMA (50), and APOLLOHOSP (42); consistency score of 59 reflects only 3 FCF-positive years and 3 years with ROE above 15% in the available history.
- ✗Debt-to-equity of 53.89 is elevated and flagged on a rising trend; this level is materially above pure-play pharma peers such as DRREDDY (ROE 16.1%) and CIPLA (quality score 30), where leverage profiles are typically lower.
- ✗5-year earnings CAGR of 4.8% trails the 5-year revenue CAGR of 10.4%, indicating margin or cost pressures that have diluted revenue gains into bottom-line growth.
- ✗RSI of 76.97 places the stock in overbought territory following a sharp 3-month rally of 15.98%; the nearest support level is ₹2,217, approximately 8.5% below current price.
- ·Mankind completed full redemption of ₹1,250 crore in non-convertible debentures in April 2026, per an exchange filing, eliminating that tranche of debt; total D/E of 53.89 remains elevated on a rising trend.
- ·Management flagged potential pharmaceutical price hikes within a month in response to an oil-shock from the Iran conflict affecting raw material costs, per NDTV Profit (April 2026).
- ·The Sri Lankan subsidiary closure was formally approved by the board in April 2026, representing a portfolio rationalisation; the financial materiality of this closure is not quantified in available data.
- ?Does the compression from trailing PE 56.0x to forward PE 40.6x reflect realistic earnings growth, or does it depend on a reversal of the 5-year trend where earnings (4.8% CAGR) have consistently lagged revenue growth (10.4% CAGR)?
- ?Is the rising debt-to-equity trend (currently 53.89) accompanied by improving return metrics that would justify the incremental leverage, and how does management describe its capital allocation priorities?
- ?Given that the recent 3-month price gain of 15.98% follows a near-flat 12-month period (+2.34%), what specific catalysts drove the recent re-rating and are they recurring or one-time in nature?
- ?How does Mankind's domestic branded generics franchise compare to peers on pricing power and market share, and to what extent does the Iran-oil-shock cost headwind affect margin guidance for FY27?
PE
56.0
Forward PE
40.6
ROE
—
Profit margin
+12.8%
D/E
53.89
Dividend yield
+0.1%
Quality score
36/100
ROE 5y above 15%
3/5 yrs
FCF 5y positive
3/5 yrs
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.Analysis generated 11 May 2026.